Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Kerry Lynn Reynolds, M.D.

Co-Author

This page shows the publications co-authored by Kerry Reynolds and Leyre Zubiri.
Connection Strength

6.560
  1. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.927
  2. Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist. 2021 08; 26(8):e1427-e1433.
    View in: PubMed
    Score: 0.909
  3. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21.
    View in: PubMed
    Score: 0.820
  4. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
    View in: PubMed
    Score: 0.820
  5. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.244
  6. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.229
  7. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.229
  8. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Curr Treat Options Oncol. 2021 05 26; 22(6):53.
    View in: PubMed
    Score: 0.228
  9. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.225
  10. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist. 2021 01; 26(1):49-55.
    View in: PubMed
    Score: 0.219
  11. Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. Front Immunol. 2022; 13:871452.
    View in: PubMed
    Score: 0.060
  12. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol. 2022 Feb 01; 158(2):189-193.
    View in: PubMed
    Score: 0.060
  13. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022 03; 163:108-118.
    View in: PubMed
    Score: 0.060
  14. Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction. Nephrol Dial Transplant. 2021 12 31; 37(1):187-189.
    View in: PubMed
    Score: 0.059
  15. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2021 12 02; 36(12):2241-2247.
    View in: PubMed
    Score: 0.059
  16. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2022 01 01; 40(1):12-23.
    View in: PubMed
    Score: 0.059
  17. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer. 2021 Oct 15; 158:99-110.
    View in: PubMed
    Score: 0.058
  18. Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. Am J Kidney Dis. 2022 01; 79(1):134-137.
    View in: PubMed
    Score: 0.057
  19. Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv. 2021 Jan; 1(1):ltab014.
    View in: PubMed
    Score: 0.057
  20. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 06; 9(6).
    View in: PubMed
    Score: 0.057
  21. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. J Immunother Precis Oncol. 2021 May; 4(2):35-44.
    View in: PubMed
    Score: 0.057
  22. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist. 2021 08; 26(8):685-693.
    View in: PubMed
    Score: 0.057
  23. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):e898-e901.
    View in: PubMed
    Score: 0.056
  24. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.056
  25. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.056
  26. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J Vasc Interv Radiol. 2021 02; 32(2):187-195.
    View in: PubMed
    Score: 0.056
  27. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021 01; 9(1).
    View in: PubMed
    Score: 0.055
  28. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Heart Assoc. 2020 12; 9(23):e018306.
    View in: PubMed
    Score: 0.055
  29. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124.
    View in: PubMed
    Score: 0.055
  30. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 12 15; 142(24):2299-2311.
    View in: PubMed
    Score: 0.054
  31. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.054
  32. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol. 2021 02; 34(2):426-437.
    View in: PubMed
    Score: 0.054
  33. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney Int Rep. 2020 Oct; 5(10):1700-1705.
    View in: PubMed
    Score: 0.054
  34. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020 06 16; 141(24):2031-2034.
    View in: PubMed
    Score: 0.053
  35. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 06 20; 395(10241):1907-1918.
    View in: PubMed
    Score: 0.053
  36. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019 12 06; 14(12):1692-1700.
    View in: PubMed
    Score: 0.051
  37. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep; 181(3):211-219.
    View in: PubMed
    Score: 0.050
  38. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 03; 82(3):743-746.
    View in: PubMed
    Score: 0.050
  39. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999.
    View in: PubMed
    Score: 0.050
  40. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019 05; 94(5):563-574.
    View in: PubMed
    Score: 0.049
  41. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol. 2019 03 01; 5(3):358-365.
    View in: PubMed
    Score: 0.049
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.